Role of Nemolizumab and Omalizumab in management of atopic dermatitis: A review
Maram Salim S Algrani, Shumoukh Saleh F AlAfnan, Yousef Hussain J Alharthi, Mohammed Abdulhafith R Alotaibi, Ali Abdulrahman A Alshehri, Rayyan Fahad H Altemani, Sultan Makki M Alsharef, Ahmed Saad A Albalawi, Yousef Ali H Alaenzi, Omnia Abdulmonum A Alali, Muneera Saeed F Alhayan, Shifa Sameer A Nagadi, Zahra Shaker H Al-kalaif, Ahmed Bakheet N Alharbi, Ibrahim Mahmoud H Ajwah
Abstract
Background
Nemolizumab (CIM331) is a monoclonal antibody that binds the IL-31 receptor α component. This inhibits IL-31 from acting on neurons that constrains the initialization of the sense of pruritus in cases of atopic dermatitis.
Aims
To summarize the results of reported studies evaluating the role of nemolizumab and omalizumab in management of atopic dermatitis.
Methods
This is a systematic review was carried out, including PubMed, Google Scholar, and EBSCO that examining randomized controlled trials, observational, and experimental studies which study role of nemolizumab in management of atopic dermatitis.
Results
The review included 8 randomized studies reported efficacy of both nemolizumab and omalizumab for management of atopic dermatitis.
Conclusion
Other studies with large numbers of patients with AD are necessary to define the adverse effects of both drugs in the treatment of AD.
Full Text:
Nemolizumab (CIM331) is a monoclonal antibody that binds the IL-31 receptor α component. This inhibits IL-31 from acting on neurons that constrains the initialization of the sense of pruritus in cases of atopic dermatitis.
Aims
To summarize the results of reported studies evaluating the role of nemolizumab and omalizumab in management of atopic dermatitis.
Methods
This is a systematic review was carried out, including PubMed, Google Scholar, and EBSCO that examining randomized controlled trials, observational, and experimental studies which study role of nemolizumab in management of atopic dermatitis.
Results
The review included 8 randomized studies reported efficacy of both nemolizumab and omalizumab for management of atopic dermatitis.
Conclusion
Other studies with large numbers of patients with AD are necessary to define the adverse effects of both drugs in the treatment of AD.
PDF